[Form 4] MYRIAD GENETICS INC Insider Trading Activity
Rhea-AI Filing Summary
Margaret Ancona, EVP, Strategy & Transformation at Myriad Genetics (MYGN), reported a non-derivative transaction on 09/21/2025 in which 958 shares of Myriad common stock were withheld at an effective price of $7.77 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the withholding, the reporting person beneficially owns 127,726 shares directly. The Form 4 filing indicates the withholding was calculated using the closing price on September 19, 2025, and the Form was submitted on 09/22/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine tax-withholding on vested RSUs; small share movement, negligible market impact.
The reported disposition of 958 shares represents withholding to cover taxes on vested restricted stock units rather than a voluntary sale for liquidity. The transaction size is small relative to the reporter's total beneficial holding of 127,726 shares, and the per-share price of $7.77 reflects the mechanics of withholding rather than a market-driven trade. For investors, this is a standard insider administration event with no direct signal about company performance.
TL;DR: Administrative RSU settlement; confirms ongoing equity-based compensation to an executive.
The Form 4 shows the company uses equity compensation (RSUs) for retention or incentive purposes and that withholding was used to satisfy tax obligations upon vesting. This is routine governance documentation: it demonstrates compliance with disclosure rules and provides transparency about executive equity holdings. The remaining beneficial ownership figure is disclosed, which aids shareholder oversight but does not indicate material governance changes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 958 | $7.77 | $7K |
Footnotes (1)
- [object Object]